Manufacturing for originator molecules is restricted by regulations, but drug makers can exploit newer technologies for the manufacture of biosimilars.
Catherine Shaffer
Advertisement
Catherine Shaffer is a contributing writer to BioPharm International, cathshaffer@gmail.com.
Articles by Catherine Shaffer
A multi-pronged approach to raw materials testing can help mitigate the risk of future contamination events.
Advertisement
Latest Updated Articles
Ensuring the Biological Integrity of Raw MaterialsPublished: February 1st 2017 | Updated:
Cost Considerations Drive Lean Technology in Biopharmaceutical ManufacturingPublished: March 1st 2017 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
